HOLON, Israel, January 30, 2017 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call on Wednesday, February 15, 2017 at 10:00 AM EST to review fourth quarter and yearend 2016 results. Compugen participants on the conference call will include Martin Gerstel, Chairman; Dr. Anat Cohen-Dayag, President and CEO; and Ari Krashin, CFO. The quarterly and yearend results will be released on the Company's website (http://www.cgen.com) prior to the call.
To access the conference call, please dial 1-888-668-9141 from the US, or +972-3-9180609 internationally. The call will also be available via live webcast through Compugen's website, located at the following link.
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-326-9310 from the US or +972-3-9255904 internationally. The replay will be available through February 18, 2017.
Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.
Director, Investor Relations and Corporate Communications
SOURCE Compugen Ltd.